Combination of Cetuximab & MWT Inhibitor Savolitinib in the Treatment of Ras Wild-Type Colorectal Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Cetuximab (Primary) ; Savolitinib (Primary)
- Indications Colorectal cancer; Head and neck cancer
- Focus Adverse reactions
- 24 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Jun 2017 Biomarkers information updated
- 23 Aug 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017.